Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

@article{Sever2014TherapeuticOF,
  title={Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.},
  author={Matjaz Sever and Kate J. Newberry and Srdan Verstovsek},
  journal={Leukemia & lymphoma},
  year={2014},
  volume={55 12},
  pages={
          2685-90
        }
}

• Matjaz Sever, Kate J. Newberry, Srdan Verstovsek
• Published 2014 in Leukemia & lymphoma
• DOI:10.3109/10428194.2014.893310

Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistance is associated with disease transformation and reduced survival. However, given the dearth of large-scale controlled clinical trials in this patient population, there is no clear… CONTINUE READING

Save to Library

Create Alert

Cite

View Paper